The PAC-1 Phase 1 clinical trial in cancer patients is beginning at the University of Illinois Cancer Center in Chicago. For more information please see the listing on clinicaltrials.gov
Cancer drug tested in pet dogs is now bound for human trials:
Champaign, Ill. — Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials. The compound, known as PAC-1, has so far proven safe and has promising anti-cancer effects in cell culture, in mouse models of cancer and in pet dogs with spontaneously occurring lymphomas and osteosarcomas.
If PAC-1 (pack one) makes it through the U.S. Food and Drug Administration’s Investigational New Drug review, the first human (Phase I) clinical trial of the drug will begin in mid-2014. The investor, who wishes to remain anonymous, has an option to invest another $2 million to take the drug into human trials. The clinical work will be conducted at the University of Illinois Cancer Center in Chicago.
University of Illinois, Urbana-Champaign Office of Technology Management:
Urbana, IL – Vanquish Oncology, Inc. is a drug development company focused on targeting molecular defects in specific cancer cells to create personalized oncology therapeutics for unmet or underserved cancer markets.
Vanquish Oncology focuses on small molecule compounds developed by Professor Paul Hergenrother of the Department of Chemistry at the University of Illinois at Urbana-Champaign which target cell apoptosis (cell death) across multiple tumor types. Pre-clinical data indicate that clinical candidates are well tolerated and efficacious in rodents and canines. Additionally, the compounds exhibit synergistic effects when used in combination with common front-line anti-cancer agents.